Flupentixol%2525252520and%2525252520melitracen

# Flupentixol and Melitracen ## Overview This combination product contains **flupentixol**, a thioxanthene antipsychotic (dopamine receptor antagonist), and **melitracen**, a tricyclic antidepressant (TCA). It is marketed primarily for the management of mild to moderate anxiety, depression, and psychosomatic disorders. ## Primary Indications - Mild to moderate depression and anxiety. - Psychosomatic conditions accompanied by apathy, fatigue, or mood disturbances. - Neurasthenia and depressive neuroses. ## Adult Dosing The typical initial dosage is **1 tablet twice daily** (morning and noon). - **Maintenance:** 1 tablet daily (morning). - **Maximum:** 2 tablets per day. - **Timing:** Avoid evening doses due to the potential for insomnia caused by the stimulant effect of melitracen and the activating profile of flupentixol. ## Pediatric Dosing **Not recommended.** Safety and efficacy have not been established in children or adolescents. Use is generally contraindicated in pediatric populations due to potential psychiatric and cardiac risks associated with TCAs and antipsychotics. ## Dose Adjustments - **Elderly:** Start at the lowest possible dose (1 tablet daily) and monitor closely for orthostatic hypotension and anticholinergic effects. - **Renal/Hepatic Impairment:** Use with caution. No specific dose titration protocols exist, but reduced frequency is advised due to the risk of accumulation. ## Contraindications - Hypersensitivity to thioxanthenes or TCAs. - Circulatory collapse, depressed levels of consciousness (e.g., alcohol or opioid intoxication). - Blood dyscrasias. - Recent myocardial infarction, heart block, or severe cardiac arrhythmias (due to melitracen). - Pheochromocytoma. - Concurrent use with Monoamine Oxidase Inhibitors (MAOIs). ## Adverse Effects - **Common:** Insomnia, restlessness, dry mouth, blurred vision, constipation, and tremor. - **Serious:** Extrapyramidal symptoms (EPS), tardive dyskinesia, QT interval prolongation (arrhythmia risk), urinary retention, and seizures. - **Rare:** Neuroleptic Malignant Syndrome (NMS), agranulocytosis. ## Key Drug Interactions - **MAOIs:** Risk of hypertensive crisis or serotonin syndrome; wait at least 14 days after discontinuing an MAOI. - **CNS Depressants:** Potentiates effects of alcohol, barbiturates, and benzodiazepines. - **Antihypertensives:** May antagonize the effects of guanethidine or similar agents. - **Anticholinergics:** Increased risk of paralytic ileus or confusion, especially in the elderly. - **QT-prolonging drugs:** Avoid concurrent use with medications that prolong the QT interval (e.g., macrolides, antiarrhythmics). ## Monitoring - **Cardiac:** Baseline and periodic ECG, especially in patients with pre-existing cardiac conditions. - **Psychiatric:** Monitor for worsening depression, suicidal ideation, or emergence of akathisia/EPS. - **Physical:** Monitor orthostatic blood pressure, body weight, and signs of urinary retention. ## Clinical Pearls - **Activating Profile:** Unlike many typical antipsychotics, this combination is activating; ensure the second dose is taken no later than early afternoon to prevent sleep disturbance. - **Withdrawal:** Abrupt cessation may lead to withdrawal symptoms (nausea, headache, malaise); taper gradually. - **Overdose Risk:** Overdosage is dangerous due to the TCA component (melitracen), which can cause life-threatening cardiac arrhythmias. *** **Educational Disclaimer:** This information is for educational purposes only. Dosing, contraindications, and drug interactions may vary by regional manufacturing standards and local prescribing protocols. Always verify current prescribing information in official resources (e.g., local formulary, product monograph, or SPC) before administration.